Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/bjc.2014.476 http://scihub22266oqcxt.onion/10.1038/bjc.2014.476 C4453440!4453440!25180764     free     free     free       Br+J+Cancer 2015 ; 112 (2): 217-26 Nephropedia Template TP {{tp|p=25180764|t=2015. Beyond BRAF: where next for melanoma therapy?|pdf=|usr=}}{{25180764}} gab.com Text Beyond BRAF: where next for melanoma therapy JO: Br J Cancer http://www.kidney.de/pget.php?&tw=1&pmid=25180764 #FOAvip In recent years, melanoma has become a poster-child for the development of oncogene-directed targeted therapies. This approach, which has been exemplified by the development of small-molecule BRAF inhibitors and the BRAF/MEK inhibitor combination for BRAF-mutant melanoma, has brought new hope to patients. Despite these successes, treatment failure seems near inevitable in the majority of cases?even in individuals treated with the BRAF/MEK inhibitor doublet. In the current review, we discuss the future of combination strategies for patients with BRAF-mutant melanoma as well as the emerging therapeutic options for patients with NRAS-mutant and BRAF/NRAS-wild-type melanoma. We also outline some of the newest developments in the in-depth personalisation of therapy that should allow melanoma treatment to continue shaping the field precision cancer medicine. Twit Text FOAVip Beyond BRAF: where next for melanoma therapy ????Br J Cancer http://www.kidney.de/pget.php?&tw=1&pmid=25180764 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=25180764 #FOAvip English Wikipedia <ref>{{Cite pmid|25180764}}</ref> Beyond BRAF: where next for melanoma therapy? #MMPMID25180764 Fedorenko IV; Gibney GT; Sondak VK; Smalley KSM Br J Cancer 2015[Jan]; 112 (2): 217-26 PMID25180764show ga In recent years, melanoma has become a poster-child for the development of oncogene-directed targeted therapies. This approach, which has been exemplified by the development of small-molecule BRAF inhibitors and the BRAF/MEK inhibitor combination for BRAF-mutant melanoma, has brought new hope to patients. Despite these successes, treatment failure seems near inevitable in the majority of cases?even in individuals treated with the BRAF/MEK inhibitor doublet. In the current review, we discuss the future of combination strategies for patients with BRAF-mutant melanoma as well as the emerging therapeutic options for patients with NRAS-mutant and BRAF/NRAS-wild-type melanoma. We also outline some of the newest developments in the in-depth personalisation of therapy that should allow melanoma treatment to continue shaping the field precision cancer medicine. äBeyond BRAF: where next for melanoma therapy?(epmc).pdf DeepDyve Pubget Overpricing